Everolimus

Everolimus 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Digestive System Neuroendocrine Tumor G1、Metastatic Digestive System Neuroendocrine Tumor G2、Unresectable Digestive System Neuroendocrine Tumor G1、Unresectable Digestive System Neuroendocrine Tumor G2。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Everolimus 研究

• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  III 期招募中美国Argentina澳大利亚比利时NCT07062965

• Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

  不适用招募中西班牙NCT07190690

• Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

  不适用招募中美国NCT04199026

• Rapalog Pharmacology (RAP PAC) Study

  I 期招募中美国NCT05949658

• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

  II 期招募中意大利NCT04893785

• Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

  II 期招募中South KoreaNCT06837792

• SNF Platform Study of HR+/ HER2-advanced Breast Cancer

  II 期招募中中国NCT05594095

• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

  II 期招募中中国NCT06482086

• 177Lu-DOTATATE for Recurrent Meningioma

  II 期招募中奥地利法国德国挪威NCT06326190

• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

  II 期招募中美国加拿大NCT05773274

• Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

  II 期招募中中国NCT04803318

• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

  IV 期招募中美国NCT07426484

• REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia

  不适用招募中英国NCT07270575

• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  II 期招募中美国NCT07340541

• Sapu003 in Advanced mTOR-sensitive Solid Tumors

  I 期招募中澳大利亚NCT07369505

• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

  II 期招募中法国NCT02029001

• FUSCC Refractory TNBC Platform Study (FUTURE2.0)

  II 期招募中中国NCT05749588

• Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

  I 期招募中美国NCT04485559

• An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

  II 期招募中中国NCT07037238

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  II 期招募中美国NCT04665739

• EVR and EPO for Liver Transplant Tolerance

  I 期招募中美国NCT06832189

• Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  II 期招募中法国NCT06254248

• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  II 期招募中美国澳大利亚加拿大德国NCT05843253

• Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

  II 期招募中BrazilNCT06472388

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。